AtriCure, Inc. (ATRC)
NASDAQ (NMS) NASDAQ (NMS) Primary 
XFRA 
Is AtriCure (ATRC) Stock Outpacing Its Medical Peers This Year?
Here is how AtriCure (ATRC) and Cidara Therapeutics (CDTX) have performed compared to their sector so far this year.
AtriCure, Inc. (ATRC) Presents at UBS Global Healthcare Conference 2025 Transcript
AtriCure, Inc. ( ATRC ) UBS Global Healthcare Conference 2025 November 10, 2025 2:00 PM EST Company Participants Angela Wirick - Chief Financial Officer Michael H. Carrel - CEO, President & Director Conference Call Participants Danielle Antalffy - UBS Investment Bank, Research Division Presentation Danielle Antalffy UBS Investment Bank, Research Division Well, good afternoon, everyone.
AtriCure (ATRC) Loses 13.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for AtriCure (ATRC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Here's What Key Metrics Tell Us About AtriCure (ATRC) Q3 Earnings (Revised)
While the top- and bottom-line numbers for AtriCure (ATRC) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Is AtriCure (ATRC) Outperforming Other Medical Stocks This Year?
Here is how AtriCure (ATRC) and Cabaletta Bio, Inc. (CABA) have performed compared to their sector so far this year.
AtriCure, Inc. (ATRC) Q3 2025 Earnings Call Transcript
AtriCure, Inc. ( ATRC ) Q3 2025 Earnings Call October 29, 2025 4:30 PM EDT Company Participants Michael H. Carrel - CEO, President & Director Angela Wirick - Chief Financial Officer Conference Call Participants Marissa Bych - Gilmartin Group LLC John Young - Canaccord Genuity Corp., Research Division Lilia-Celine Lozada - JPMorgan Chase & Co, Research Division Marie Thibault - BTIG, LLC, Research Division John McAulay - Stifel, Nicolaus & Company, Incorporated, Research Division Joseph Conway - Needham & Company, LLC, Research Division Danielle Antalffy - UBS Investment Bank, Research Division Presentation Operator Good afternoon, and welcome to AtriCure's Third Quarter 2025 Earnings Conference Call.
Here's What Key Metrics Tell Us About AtriCure (ATRC) Q3 Earnings
While the top- and bottom-line numbers for AtriCure (ATRC) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
AtriCure (ATRC) Reports Q3 Loss, Beats Revenue Estimates
AtriCure (ATRC) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to a loss of $0.17 per share a year ago.
AtriCure, Inc. (ATRC) Q2 2025 Earnings Call Transcript
AtriCure, Inc. (NASDAQ:ATRC ) Q2 2025 Earnings Conference Call July 29, 2025 4:30 PM ET Company Participants Angela L. Wirick - Chief Financial Officer Michael H.
AtriCure (ATRC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for AtriCure (ATRC) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
AtriCure (ATRC) Reports Q2 Loss, Tops Revenue Estimates
AtriCure (ATRC) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.17 per share a year ago.
Does AtriCure (ATRC) Have the Potential to Rally 54.7% as Wall Street Analysts Expect?
The consensus price target hints at a 54.7% upside potential for AtriCure (ATRC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
